Aquaporin 4
From Proteopedia
| |||||||||
| Human Aquaporin 4 complex with glycerol and β-octylglucoside, 3gd8 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ligands: | , | ||||||||
| Gene: | AQP4 (Homo sapiens) | ||||||||
| |||||||||
| |||||||||
| Resources: | FirstGlance, OCA, RCSB, PDBsum | ||||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||||
Higher Order Structure of AQP4
AQP4 is organized in the plasma membrane into structures called orthogonal arrays of particles (OAPs). These structures are comprised of both the M23 and M1 isoforms of AQP4, though M23 is specifically required for the formation of OAPs as the amino acid sequence of the N-terminus of the M1 isoform appears to prevent formation of OAPs [4]. The recognition of AQP4’s role in the formation and structure of OAPs has led to further understanding in several neuromuscular diseases, including Duchenne Muscular Dystrophy, and NMO (see “Role in Autoimmune Disorders” below). There is also evidence that the formation of OAPs is physiologically regulated [5].
Role in Autoimmune Disorder
Clinical presentations of central nervous system (CNS) aquaporin-4 autoimmunity are consistent with neuromyelitis optica (NMO), and can include blindness and paraplegia. Previously, variants of the NMO phenotype were classified as differential presentations of Multiple Sclerosis (MS). The specific causes of CNS AQP4 autoimmunity are unknown. However, observations of two patients with brain metastases suggest that CNS AQP4 autoimmunity may develop as part of an immune response to cancer [7]. As is the case in many autoimmune disorders, treatment of CNS AQP4 autoimmunity with anti-inflammatories (such as corticosteroids) and antibody-depleting therapeutics (such as plasma exchange) have been effective at reducing symptoms. Therapies for NMO based on the role of CNS AQP4 autoimmunity await further experimentation of the disease model and cell culture systems. [8]
References
1. Crane, J.M., Tajima, M., and Verkman, A.S. Live-cell imaging of aquaporin-4 diffusion and interactions in orthogonal arrays of particles. Neuroscience (2010) vol. 168 (4) pp. 892-902
2. Hiroaki, Y., Tani, K., Kamegawa, A., Gyobu, N., Nishikawa, K., Suzuki, H., Walz, T., Sasaki, S., Mitsuoka, Kimura, K., Mizoguchi, A., and Fujiyoshi, Y. Implications of the aquaporin-4 structure on array formation and cell adhesion. J Mol Biol (2006) vol. 355 (4) pp. 628-39
3. Nicchia, G.P., Rossi, A., Mola, M.G., Pisani, F., Stigliano, C., Basco, D., Mastrototaro, M., Svelto, M., and A. Frigeri. Higher order structure of aquaporin-4. Neuroscience (2010) vol. 168 (4) pp. 903-14
4. Pittock SJ, and Lennon V.A. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch Neurol (2008) 65:629–632.
5. Hinson, S.R., McKeon, A., and Lennon V.A. Neurological autoimmunity targeting aquaporin-4. Neuroscience (2010) vol. 168 (4) pp. 1009-18.
6. Saadoun S., Papadopoulos M.C., Hara-Chikuma M, Verkman A.S. Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption. Nature (2005) 434:786–792.
7. Verkman A.S., Hara-Chikuma M., Papadopoulos M.C. Aquaporins—new players in cancer biology. J Mol Med (2008) 86:523–529.

